The diabetic dog represents an excellent model for use in many aspects of diabetic research. The present paper describes, in detail, a reproducible experimental protocol for the successful induction of chemical diabetes in beagles using a combination of the 2 pancreatic beta-cell cytoxic agents alloxan and streptozotocin.
The diabetic dog represents an excelIent model for the study of diabetic retinopathy as it reproduces alI but the very late changes observed in the human diabetic eye (Engerman et al., 1977; Black et al., 1980; Engerman et al., 1982) .
In the majority of previous studies the techniques employed to induce chemical diabetes in dogs have involved the use of one of the 2 pancreatic beta-cell cytoxic agents alloxan and streptozotocin (Engerman et al., 1977; Engerman & Bloodworth, 1965; Rakieten et al., 1963) .
However, a major drawback of these methods was a high mortality of animals. When administered singly, the diabetogenic doses of alloxan and streptozotocin required had adverse effects on other organ systems. Also, many animals were lost through a severe hypoglycaemic episode caused by insulin dumping from injured beta-cells in the acute period (during the first 24 h).
Correspondence to: Dr HR Anderson. Received 23 October 1992; accepted 20 January 1993 The combination of alloxan and streptozotocin to induce diabetes has the advantage of allowing the use of lower doses of both drugs than if either was used singly (Issekutz et al., 1974) . High doses of alIoxan and streptozotocin can have toxic effects on other organ systems causing severe liver and kidney damage including necrosis and fatty infiltration (Rerup, 1970) . However, a detailed study of the biochemical and morphological changes which occur folIowing administration of the drug combination has shown no evidence of any significant toxicity to organs other than the pancreas (Black et 01., 1980) . The present paper proposes a detailed experimental regimen, outlining further refinements to previous techniques in the induction of alloxan/ streptozotocin diabetes in dogs without severe hypoglycaemia or mortality.
Materials and methods
The study involved adult laboratory bred beagles which were obtained from a commercial supplier and housed in conventional laboratory conditions in accordance with the Home Office Code of Practice (Home Office, 1989) . The dogs were divided into 2 groups; Group I. Twenty beagle dogs aged between 4, 5 and 5 months and weighing 11-17 kg.
Group II. Four beagle dogs aged between 14 and 17 months and weighing 19-24 kg.
All dogs used in the study were housed in individual kennels and fed twice daily (morning and evening) on a diet of tripe and biscuit fortified with vitamins and minerals.
On the morning of induction of diabetes alI dogs were fed once and then fasted for the rest of the day. from normal (5 mM/I) to between 3 and 4 mM/1. At this time all dogs were given an intravenous drip of 0'9070NaCI containing 5070dextrose. From this point onwards the exogenous supply of sugar in tr.e intravenous drips caused an artificial increase in circulating blood glucose levels and thus prevented any potentially dangerous hypoglycaemic episodes ( Fig. 1) .
Over the following 7-8 h all dogs received between 2000 ml and 2500 ml of 5070dextrose saline. Throughout this period blood glucose was measured at haJ-hourly intervals and the dextrose drip adjusted accordingly. In a pilot study in which alloxan/streptozotocin diabetes was induced in 10 c.ogs it was observed that when the IV dextrose was replaced with Hartmans solution the dogs blood sugar fell precipitously. By periodically substituting the IV dextrose with Hartmans and measuring the animals' blood glucose within 20 min it was determined that dextrose infusion was required up to 16 h post induction. After this time the animals' blood glucose remai:1ed within or above normal limits when the dextrose was withdrawn and the infusion could be discontinued. Thus in the present experiment all dogs were taken off their drips after 16 h and they slowly became hyperglycaemic so that on the second day after drug administration the average blood glucose of the dogs in group I had risen to a high level The same evening (12-14 h after feeding) the dogs were each given a single intravenous (IV) injection of an alloxan (40 mg/kg)/streptozotocin (35 mg/kg) mixture via the cephalic vein in the foreleg. Both drugs were initially prepared aseptically as solutions containing 100mg/ml in trisodi urn citrate buffer, pH 4· 5 and sterilized by filtration through 0·22 /lm filters. The drug solutions were prepared immediately before administration as the compounds display chemical instability in solution.
Approximately 8 h after drug treatment each dog was placed in a Pavlov sling and administered 0,9070NaCI saline containing 5070 dextrose through an intravenous drip into either the cephalic vein in the foreleg or the sephanous vein in the hind leg. The dogs were maintained on dextrose saline for a further 8-9 h in order to prevent any hypoglycaemic episodes. Throughout, the dogs were kept under constant supervision and blood glucose levels were measured hourly with an Ames glucometer reflectance photometer. The flow rate of the saline/dextrose drip was adjusted accordingly to ensure that blood glucose levels did not fall below 5mM/1. The dogs were then taken off the drips (approximately 16h post drug administration), returned to their kennels and fed.
The next morning (approximately 34 h post drug administration), blood glucose was measured and each dog given 2 units of insulin by subcutaneous injection. Blood glucose levels were measured several times throughout the course of the day and each dog was given a further injection of insulin later in the day according to the blood glucose level.
Every day thereafter, blood glucose levels were measured first thing in the morning before feeding and the dose of insulin altered to maintain a blood glucose level of between 15 and 23 mM/1.
Results
Dogs in both groups showed a similar initial response over the first 16 h after alloxan/ streptozotocin treatment. At 9 h post drug administration blood glucose levels had fallen (<22' 2 mM/l) and in group II the average blood glucose level was 20 mM/1.
All group I dogs were successfully maintained at a blood glucose level of around 20 mM/1 for a period of 16 weeks requiring between 17 and 49 units of insulin per day (Fig. 2a ). These dogs all remained healthy, retained a normal appetite and gained weight. Fig. 2a shows that the average blood glucose level of the 4 dogs in group II decreased over the first 5 weeks to around 11 mM/1 and then increased slightly to 13 mM/1 after 10 weeks. However, examination of the individual weekly blood glucose levels of each dog in group II
Discussion
Results show that dogs in both groups I and II reacted similarly over the first 16 h following the administration of an alloxan/streptozotocin cocktail. The marked decrease in blood glucose observed 8 to 9 h after drug treatment had been anticipated, such a phenomena having been described in previous studies which attributed it to a release of insulin from the damaged pancreatic beta cells (Black et al., 1980) . Therefore, in order to prevent the occurrence of severe, life-threatening hypoglycaemia, in the present study, dogs were given an intravenous drip of 0·9% NaCl saline containing 5070 dextrose. This allowed the animals' blood glucose to be maintained at or above normal limits and no dogs were lost through hypoglycaemia during the induction period of the study. The success of this measure in preventing fatality is particularly significant since severe hypoglycaemia shortly after drug administration has previously represented one of the major problems with survival following chemically induced diabetes in experimental animals. The importance of the continuous drip was shown in the case of one dog whose blood glucose level fell to I· 7 mM/1 after receiving saline solution only with no added dextrose over a 2 h period. All dogs were taken off the drips at 16 h post shows that the reaction of each dog to the aIIoxan/ streptozotocin treatment was variable (Fig. 2b) . Dogs 2, 3 and 4 showed a gradual decline in blood glucose levels over a 9-week period and they stopped requiring exogenous insulin between 4 and 5 weeks. However, dog 1 showed an initial overall decline in blood glucose to about 15 mM/1 and required only 6-7 units of insulin per day after 5 weeks. Its blood glucose level then increased so that from 6 weeks onwards the blood glucose level was high ( < 22· 2 mM/1) and its insulin requirements increased from 7 to 26 units per day. All 4 dogs remained difficult to feed and lost weight over the 9-week period of study. Dogs 2, 3 and 4 showed severe weight loss, and eventually all 3 were culled between 7 and 9 weeks post drug administration. drug administration by which time all the insulin released by the damaged beta cells had been metabolized and the dogs' own blood sugar had begun to increase. The use of an intravenous drip allows an immediate and continual supply of glucose into the blood stream and resulted in an increase in blood sugar after only I h. This method represents a significant improvement over that used by Black et al. (1980) in which 4 subcutaneous injections of glucose (50-100ml, 10OJo dextrose) were administered at 8, 11, 13 and 16h post-drug treatment. Large subcutaneous injections of 10OJo dextrose may be highly irritant and the study by Black et al. (1980) failed to prevent hypoglycaemia, the blood sugar remaining low for between 7 and 12 h.
Results from the present study showed a difference in the way in which dogs of different ages/weights reacted to the induction of diabetes by alIoxan/streptozotocin. Thus, all dogs in the weight range 11-17 kg responded well to drug treatment and showed a lOOOJo survival rate while alI the older/heavier dogs in the study (19-24 kg, 14-17 months) were difficult to maintain as diabetics, lost weight and ultimately became ill. This suggests that there is an optimum agel weight of dogs which should be used in diabetic studies of this nature (between 11 and 17 kg, i.e. 4, 5-5 months of age). The ages and weights of dogs used in previous diabetic studies have varied considerably, for example 6-11 kg (Rakieten et al., 1963 ), 8-13 kg (Black et al., 1980 ), 18-30 months (Kern & Engerman, 1988 and dogs have even been used when their ages were only an estimate and ranged from 3-13 years (Engerman et al., 1977) .
The results from a number of these studies are difficult to aSSess as the dogs were of different ages and breeds while those in the present study were healthy young beagles of the same sex and from the same colony. As current legislation in Great Britain restricts the supply of animals for medical research to those from reputable commercial establishments and other registered breeding units it should not be difficult for researchers undertaking future diabetic studies in the dog to cos': for and obtain animals of the optimal age/wei:~ht and sex.
Induction of iiabetes by a combination of alloxan and streptozotocin allows the use of drug levels considerably below the diabetogenic dose, if either drug was used independently. Previous studies employing this cocktail combination to induce diabetes used doses of 50 mg/kg alloxan and 30 mg/kg streptozotocin (Black et al., 1980; Isselkutz et al., 1974) . Alloxan, if used in such large doses is known to have toxic effects on other organ sy~:tems causing severe liver and kidney damage (Rerup, 1970) . Since drugs were administered or. a weight basis, it is likely that the ill health and poor survival of the heavier dogs in the present study was caused by toxic effects of the large doses of alloxan which they received. At autopsy dogs 2, 3 and 4 showed severe hepatic necrosis with extensive fatty infiltration, a condition previously described in dogs after administration of high doses of alloxan (Rerup, 1970) . Administration of alloxan and streptozotocin on a body-surface basis rather than on a weigH basis would have resulted in the heavier dogs receiving proportionately smaller doses of the 2 drugs. However, while these lower drug doses may have reduced the toxic effects they are unlikdy to have induced diabetes as 3 of the 4 dogs in group II did not become diabetic after administration of the higher drug doses.
Other techni~al modifications employed in the present investigation include the use of dogs all of the same sex (male) and the same breed (beagle). In previous studies, dogs of both sexes were often used (Rakieten et al., 1963; Kern & Engerman, 1988; Kern & Engerman, 1990) , and in some, the dogs were also of different breeds (Engerman et al., 1977) .
In the present study the dogs were fasted for 12 to 14h before ldministration of the drug cocktail. Animals treated with streptozotocin/alloxan often showed initial adverse reactions to the drugs, e.g. nausea, vomiting etc. A shorter fasting period ought to help the dog withstand the rigours of these post-treatment side-effects than if they had been fasted for 24 h as in previous studies (Black et aI., 1980; Kern & Engerman, 1990 ).
The present paper presents a reproducible technique for the successful induction of chemical diabetes in dogs. The dog represents an excellent animal model for use in diabetic studies. The animals are easily handled and are known to produce retinal and kidney lesions morphologically identical to those of humans (Engerman et al., 1977; Black et al., 1980; Engerman et al., 1982; Kern & Engerman, 1988; Rerup, 1970;  
